Trial Profile

A combination study of ATG 037 and JS 207

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 30 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

30 Mar 2026 New trial record
25 Feb 2026 According to Antengene media release, company announced the clinical collaboration agreement with Shanghai Junshi Biosciences Co.. Under the collaboration, they will jointly evaluate the synergistic therapeutic potential of Antengenes ATG-037 in combination with Junshi Biosciences JS207 in patients with solid tumors in Mainland China. this collaboration builds on the encouraging Phase I proof-of-concept clinical data generated with ATG-037.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com